Antidepressants To Add Class Labeling On Pregnancy & Serotonin Syndrome
Executive Summary
Antidepressants remain at the forefront of FDA's safety focus with a pair of public health advisories on use during pregnancy and on concomitant use with triptans
You may also be interested in...
Impact of Antidepressant Black Box Juggled By Advisory Committee, FDA
The addition of new, positive data on adult suicidality to antidepressant labeling could be an opportunity to offset the negative impact the "black box" warning on pediatric suicidality has had on antidepressant use, according to members of FDA's Psychopharmacologic Drugs Advisory Committee
Impact of Antidepressant Black Box Juggled By Advisory Committee, FDA
The addition of new, positive data on adult suicidality to antidepressant labeling could be an opportunity to offset the negative impact the "black box" warning on pediatric suicidality has had on antidepressant use, according to members of FDA's Psychopharmacologic Drugs Advisory Committee
Antidepressant “Black Box” Presents Barrier To DTC Advertising
FDA's proposed "black box" warning for all antidepressants would likely mean an end to television ads for the products